...
首页> 外文期刊>American Journal of Physiology >Detrimental effects of thyroid hormone analog DITPA in the mouse heart: increased mortality with in vivo acute myocardial ischemia-reperfusion.
【24h】

Detrimental effects of thyroid hormone analog DITPA in the mouse heart: increased mortality with in vivo acute myocardial ischemia-reperfusion.

机译:甲状腺激素模拟DITPA在小鼠心脏中的不利影响:增加了体内急性心肌缺血再灌注的死亡率。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

There is emerging evidence that treatment with thyroid hormone (TH) can improve postischemic cardiac function. 3,5-Diiodothyropropionic acid (DITPA), a TH analog, has been proposed to be a safer therapeutic agent than TH because of its negligible effects on cardiac metabolism and heart rate. However, conflicting results have been reported for the cardiac effects of DITPA. Importantly, recent clinical trials demonstrated no symptomatic benefit in patients with DITPA despite some improved hemodynamic and metabolic parameters. To address these issues, dose-dependent effects of DITPA were investigated in mice for baseline cardiovascular effects and postischemic myocardial function and/or salvage. Mice were treated with subcutaneous DITPA at 0.937, 1.875, 3.75, or 7.5 mg.kg(-1).day(-1) for 7 days, and the results were compared with untreated mice for ex vivo and/or in vivo myocardial ischemia-reperfusion (I/R). DITPA had no effects on baseline body temperature, body weight, or heart rate; however, it mildly increased blood pressure. In isolated hearts, baseline contractile function was significantly impaired in DITPA-pretreated mice; however, postischemic recovery was comparable between untreated and DITPA-treated groups. In vivo baseline cardiac parameters were significantly affected by DITPA, with increased ventricular dimensions and decreased contractile function. Importantly, DITPA-treated mice demonstrated high prevalence of fatal cardiac rhythm abnormalities during in vivo ischemia and/or reperfusion. There were no improvements in myocardial infarction and postischemic fractional shortening with DITPA. Myocardial sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA), phospholamban (PLB), and heat shock protein (HSP) levels remained unchanged with DITPA treatment. Thus DITPA administration impairs baseline cardiac parameters in mice and can be fatal during in vivo acute myocardial I/R.
机译:出现了甲状腺激素(Th)的疗法可以改善发布后心肌功能。已经提出了3,5-二碘甲基丙二酸(DITPA),A类似物是一种更安全的治疗剂,而不是其对心脏代谢和心率的可忽略的影响。然而,据报道,DITPA的心脏作用据报道了相互矛盾的结果。重要的是,尽管有一些改善的血液动力学和代谢参数,但最近的临床试验表明DITPA患者没有对症状的益处。为了解决这些问题,DITPA的剂量依赖性在小鼠中研究了基线心血管作用和外部血肿心肌功能和/或挽救物。将小鼠用皮下DITPA治疗,在0.937,1.875,3.75,或7.5mg.kg(-1)时。 -reperfusion(I / R)。 DITPA对基线体温,体重或心率没有影响;然而,它温和地增加了血压。在孤立的心中,DITPA-Preproeted小鼠中基线收缩功能显着受损;然而,在未处理和DITPA治疗的基团之间的情况下出发的恢复是可比的。体内基线心脏参数受到DITPA的显着影响,心室尺寸增加和收缩功能下降。重要的是,DITPA治疗的小鼠在体内缺血和/或再灌注过程中表现出致命的心脏节律异常的高患病率。心肌梗死和DITPA没有改善。心肌Sarco(Endo)素质网Ca2 + -ATPase(Serca),磷酰胺(PLB)和热休克蛋白(HSP)水平与DITPA治疗保持不变。因此,DITPA管理损害小鼠中的基线心脏参数,并且在体内急性心肌I / R中可能是致命的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号